ARWR241220C29000
- 1.15
- 0.000.00%
Arrowhead Pharmaceuticals Newsroom
Arrowhead Pharma +17% After Signing Deal with Sarepta Therapeutics
Sector Update: Health Care Stocks Advance Tuesday Afternoon
Sector Update: Health Care
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Top Midday Gainers
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Here Are the Major Earnings After the Close Today
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
Express News | Sarepta: Co Will Nominate & Arrowhead Will Deliver Ind-Ready Constructs for 6 Targets Across Skeletal Muscle, Cardiac, CNS
Express News | Sarepta Therapeutics Inc - CEO Doug Ingram to Join Arrowhead Board
Express News | Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement With Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical Sirna Programs
Earnings Scheduled For November 26, 2024
A Look Ahead: Arrowhead Pharma's Earnings Forecast
Earnings Week Ahead: CRWD, DELL, ZM, WDAY, HPQ, M, BBY and More
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) Have Lost 75%, as Stock Drops 13% This Past Week
Earnings Preview: ARWR to Report Financial Results Post-market on November 26
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Arrowhead Pharmaceuticals' Potential Approval of Clozasiran Drives Buy Rating and $60 Price Target
Piper Sandler Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)